Astrana Health (NASDAQ:ASTH) Given New $65.00 Price Target at BTIG Research

Astrana Health (NASDAQ:ASTH) had its target price upped by BTIG Research from $50.00 to $65.00 in a research note released on Tuesday morning, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the stock.

A number of other equities research analysts have also commented on ASTH. Truist Financial upped their price target on Astrana Health from $38.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Barclays raised Astrana Health from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $37.00 to $50.00 in a research note on Tuesday, May 26th. Weiss Ratings upgraded Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Needham & Company LLC increased their target price on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, TD Cowen increased their target price on shares of Astrana Health from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Astrana Health has a consensus rating of “Moderate Buy” and an average price target of $47.86.

Astrana Health Price Performance

Shares of NASDAQ:ASTH opened at $49.00 on Tuesday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.35 and a current ratio of 1.35. Astrana Health has a 52 week low of $18.08 and a 52 week high of $51.60. The firm has a market cap of $2.73 billion, a PE ratio of 80.33 and a beta of 0.89. The firm’s fifty day moving average is $40.87 and its 200-day moving average is $30.86.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45. The business had revenue of $965.10 million during the quarter, compared to the consensus estimate of $949.21 million. Astrana Health had a return on equity of 9.22% and a net margin of 0.86%.Astrana Health’s quarterly revenue was up 55.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 earnings per share. Sell-side analysts predict that Astrana Health will post 1.25 earnings per share for the current year.

Hedge Funds Weigh In On Astrana Health

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in shares of Astrana Health by 6.5% during the 1st quarter. Royal Bank of Canada now owns 278,619 shares of the company’s stock worth $8,640,000 after buying an additional 17,028 shares during the period. AQR Capital Management LLC acquired a new position in shares of Astrana Health during the 1st quarter valued at $933,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Astrana Health by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after acquiring an additional 1,263 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Astrana Health by 4,365.2% during the first quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company’s stock worth $346,000 after acquiring an additional 10,913 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in Astrana Health by 5.8% during the first quarter. Intech Investment Management LLC now owns 44,586 shares of the company’s stock worth $1,383,000 after acquiring an additional 2,462 shares in the last quarter. 52.77% of the stock is owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.